EASE services are tailored to fit the needs of patients

1-844-900-EASE (3273) 9:00 am to 8:00 pm ET, Monday to Friday

EASE provides solutions to the potential hurdles your office and patients may encounter, with the following programs to help access CABOMETYX tablets. EASE Representatives can provide information and answer questions relating to coverage, specialty pharmacy shipments, and financial assistance options/eligibility.*

Quick Start

Your patients who experience insurance coverage decision delays don't have to wait to initiate therapy

  • A supply of CABOMETYX for new patients, with refills as needed (for up to 60 days)

How to Enroll Patients in Quick Start

  1. Complete the EASE Enrollment Form
    NOTE: Ensure patient's name and date of birth are filled out on the top of page 2
  2. Complete Quick Start prescription (Section 5)
  3. Sign Sections 5 and 6
    EASE will verify payer delay and dispense Quick Start supply until coverage determination is made for up to 60 days
If you are an in-office dispenser, please check box for "Specialty Pharmacy Referral Not Needed" (Section 4).

Dose Exchange Program

Support your patients who require dose reductions to their therapy with CABOMETYX

  • Patients receive a free one-time supply of CABOMETYX tablets in the new dose strength

How to Enroll Patients in the Dose Exchange Program

  1. Complete the Dose Exchange Form
  2. Sign and submit the form to EASE
  3. EASE ships the new dose strength tablets to your patient and helps the patient return their unused tablets

Alternate Funding Assistance

Help address access hurdles for patients who cannot afford therapy

  • PAP free product is available to patients who qualify

How to Enroll Patients in Alternate Funding Assistance

  1. Complete the EASE Enrollment Form
  2. Have patients complete and sign Patient Authorization Form
    EASE can provide assistance with alternative funding options and determine PAP eligibility
If you are an in-office dispenser, please check box for "Specialty Pharmacy Referral Not Needed" (Section 4).

Ease Co-Pay Program

(for patients with commercial insurance)

$10 Maximum Monthly Co-Pay

  • Eligible commercial patients pay no more than $10 per month, for a maximum benefit of $25,000 per year

How to Enroll Patients in the EASE Co-Pay Program

  1. Complete the EASE Enrollment Form
  2. EASE will enroll eligible commercial patients

Free Trial Program

Get your eligible new patients started with a free trial of CABOMETYX

  • To learn more, contact your local Exelixis® Oncology Account Manager
  • Limited quantities are available
For a complete list of EASE forms, please visit the Resources section

*This description of the Exelixis® Access Services program is for informational purposes only. Exelixis® makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis® Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis® reserves the right to modify the program at any time without notice.
Limited to the following ICD-10 diagnoses: C64, C64.1, C64.2, and C64.9. Other restrictions may apply.

Distributors of CABOMETYX

What happens next: Advancing your prescription to the specialty pharmacy

  1. Complete the EASE Enrollment Form
  2. EASE will enroll eligible commercial patients
Specialty Pharmacies
Accredo 1-800-803-2523 www.accredo.com
Advanced Care Scripts (ACS) 1-866-681-7131 www.acs-rx.com
Biologics, Inc. 1-800-850-4306 www.biologicsinc.com
CVS Caremark 1-800-237-2767 www.cvsspecialty.com
Diplomat 1-877-977-9118 www.diplomatpharmacy.com
Walgreens 1-888-380-6188 www.walgreenshealth.com
Specialty Distributors
Cardinal Health Specialty Distribution 1-855-740-1871 specialtyonline.cardinalhealth.com
McKesson Specialty Health 1-800-482-6700 www.mckessonspecialtyhealth.com
Oncology Supply 1-800-633-7555 www.oncologysupply.com
Institutions/Hospitals
McKesson Plasma and Biologics 1-877-625-2566 connect.mckesson.com
ASD Healthcare 1-800-746-6273 www.asdhealthcare.com
Next: Resources »

Indication

CABOMETYX™ (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.

Important Safety Information

Hemorrhage: Severe hemorrhage occurred with CABOMETYX™. The incidence of Grade ≥3 hemorrhagic events was 2.1% in CABOMETYX-treated patients and 1.6% in everolimus-treated patients. Fatal hemorrhages also occurred in the cabozantinib clinical program. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.

Gastrointestinal (GI) Perforations and Fistulas: Fistulas were reported in 1.2% (including 0.6% anal fistula) of CABOMETYX-treated patients and 0% of everolimus-treated patients. GI perforations were reported in 0.9% of CABOMETYX-treated patients and 0.6% of everolimus-treated patients. Fatal perforations occurred in the cabozantinib clinical program. Monitor patients for symptoms of fistulas and perforations. Discontinue CABOMETYX in patients who experience a fistula that cannot be appropriately managed or a GI perforation.

Thrombotic Events: CABOMETYX treatment results in an increased incidence of thrombotic events. Venous thromboembolism was reported in 7.3% of CABOMETYX-treated patients and 2.5% of everolimus-treated patients. Pulmonary embolism occurred in 3.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Events of arterial thromboembolism were reported in 0.9% of CABOMETYX-treated patients and 0.3% of everolimus-treated patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.

Hypertension and Hypertensive Crisis: CABOMETYX treatment results in an increased incidence of treatment-emergent hypertension. Hypertension was reported in 37% (15% Grade ≥3) of CABOMETYX-treated patients and 7.1% (3.1% Grade ≥3) of everolimus-treated patients. Monitor blood pressure prior to initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX for severe hypertension that cannot be controlled with anti-hypertensive therapy. Discontinue CABOMETYX if there is evidence of hypertensive crisis or severe hypertension despite optimal medical management.

Diarrhea: Diarrhea occurred in 74% of patients treated with CABOMETYX and in 28% of patients treated with everolimus. Grade 3 diarrhea occurred in 11% of CABOMETYX-treated patients and in 2% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose modification due to diarrhea occurred in 26% of patients.

Palmar-Plantar Erythrodysesthesia Syndrome (PPES): PPES occurred in 42% of patients treated with CABOMETYX and in 6% of patients treated with everolimus. Grade 3 PPES occurred in 8.2% of CABOMETYX-treated patients and in <1% of everolimus-treated patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPES or Grade 3 PPES until improvement to Grade 1; resume CABOMETYX at a reduced dose. Dose modification due to PPES occurred in 16% of patients.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Perform an evaluation for RPLS in any patient presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.

Embryo-fetal Toxicity: CABOMETYX can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the last dose.

Adverse Reactions: The most commonly reported (≥25%) adverse reactions are: diarrhea, fatigue, nausea, decreased appetite, PPES, hypertension, vomiting, weight decreased, and constipation.

Drug Interactions: Strong CYP3A4 inhibitors and inducers: Reduce the dosage of CABOMETYX if concomitant use with strong CYP3A4 inhibitors cannot be avoided. Increase the dosage of CABOMETYX if concomitant use with strong CYP3A4 inducers cannot be avoided.

Lactation: Advise a lactating woman not to breastfeed during treatment with CABOMETYX and for 4 months after the final dose.

Reproductive Potential: Contraception―Advise females of reproductive potential to use effective contraception during treatment with CABOMETYX and for 4 months after the final dose. Infertility―CABOMETYX may impair fertility in females and males of reproductive potential.

Hepatic Impairment: Reduce the CABOMETYX dose in patients with mild (Child-Pugh score [C-P] A) or moderate (C-P B) hepatic impairment. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information by clicking here.

+

Indication and Important Safety Information

Indication

CABOMETYX™ (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy.

Important Safety Information

Hemorrhage: Severe hemorrhage occurred with CABOMETYX™. The incidence of Grade ≥3 hemorrhagic events was 2.1% in CABOMETYX-treated patients and 1.6% in everolimus-treated patients. Fatal hemorrhages also occurred. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.